Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOA | P61586 | 1/20 | 0.36 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 7/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16785527 | 0.90 | MC4R (0.39) | KARS1BRAFADORA2AFYN | |
| SCHEMBL16776403 | 0.87 | MTOR (0.35) | BRAFBRD4CREBBPADORA2A | |
| SCHEMBL16776420 | 0.87 | PIM1 (0.34) | SLC5A1BRAFBRD4CREBBPADORA2A | |
| SCHEMBL16785530 | 0.86 | KARS1 (0.38) | KARS1SLC5A1KMOBRAFADORA2A | |
| SCHEMBL16776282 | 0.86 | RHOA (0.38) | RHOASLC5A1BRAFBRD4CREBBP | |
| SCHEMBL16776368 | 0.86 | RHOA (0.36) | RHOASLC5A1BRAFBRD4CREBBP | |
| SCHEMBL16785582 | 0.85 | ADORA2A (0.37) | KARS1SLC5A1KMOBRAFADORA2A | |
| SCHEMBL16776422 | 0.85 | CREBBP (0.40) | RHOASLC5A1BRAFBRD4CREBBP | |
| SCHEMBL16785531 | 0.85 | KARS1 (0.36) | KARS1SLC5A1KMOADORA2AFYN | |
| SCHEMBL16785528 | 0.84 | KIF18A (0.38) | KARS1SLC5A1KMOADORA2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RHOA 4798/4885KARS1 1760/4885SLC5A1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.